Beam Therapeutics is a biotechnology company that develops precision genetic medicines using its proprietary base editing technology. Base editing, a form of gene editing, allows for the precise rewriting of single DNA letters without creating double-strand breaks in the genetic code, a key distinction from earlier CRISPR-based methods.
The company's work sits at the intersection of several technical domains, including base editing, gene delivery, and the broader field of genetic medicines. Its operations are based in Cambridge, Massachusetts, and Research Triangle Park, North Carolina.
Beam Therapeutics describes itself as a values-driven organization committed to its people and cutting-edge science, with a team united by a passion to innovate in the genetic medicine space.
